Datasheet for ABIN7448167

GPRC5D Protein-VLP (AA 1-300)

2 Images

Go to Product page

Overview

Quantity:	100 µg
Target:	GPRC5D
Protein Characteristics:	AA 1-300
Origin:	Cynomolgus
Source:	HEK-293 Cells
Protein Type:	VLP
Biological Activity:	Active
Application:	ELISA, Functional Studies (Func), Immunogen (Imm), Surface Plasmon Resonance (SPR)

Product Details

Purpose:	Cynomolgus GPRC5D Protein-VLP
Sequence:	Met1-Cys300
Characteristics:	Recombinant Cynomolgus GPRC5D Protein-VLP is expressed from HEK293.It contains Met1-Cys300.
Purity:	> 95 % as determined by HPLC
Sterility:	0.22 µm filtered
Endotoxin Level:	Less than 1EU per µg by the LAL method.
Biological Activity Comment:	Immobilized Cynomolgus GPRC5D VLP (100µl/well) at 5µg/ml (100µl/Well) on the plate. Dose response curve for Anti-GPRC5D Antibody, hFc Tag with the EC50 of 3.8µg/ml determined by ELISA.

Target Details

Target:	GPRC5D
Alternative Name:	GPRC5D (GPRC5D Products)
Background:	Chimeric antigen receptor (CAR) T cells, a type of cell-based immunotherapy, have shown some promising results in multiple myeloma, a bone marrow cancer.The orphan G protein-coupled receptor, class C group 5 member D (GPRC5D), normally expressed only in the hair follicle, Using quantitative immunofluorescence, we determined that GPRC5D protein is expressed on CD138 MM cells from primary marrow samples with a distribution that was similar to, but independent of, BCMA.
Molecular Weight:	35.10 kDa.
UniProt:	A0A2K5W6I7

Application Details

Application Notes:	• Antibody Discovery: Immunization, Screening, Functional Characterization • Affinity determination: ELISA, SPR • In vivo pharmacokinetic analysis • CMC method development • CAR-T Positive Rate Detection • Blood sample determination: ELISA
Comment:	Virus-like particles (VLPs) are formed from the outer capsid protein of a virus and are tiny nanoparticles formed by the automatic assembly of one or more capsid proteins. VLPs do not contain viral infectious genomes, so they are relatively safe during production operations. The SAMS™ protein engineering platform has been used to express a series of biotinylated, non-biotinylated, and fluorescently-labeled VLP-displayed antigens. They are suitable for SPR, ELISA, CAR-T positive rate detection, and other experimental scenarios. Virus-Like Particles (VLPs) are highly immunogenic, meaning that they can elicit a strong immune response in the host. VLPs are recognized by the immune system and are taken up by antigen-presenting cells (APCs) such as dendritic cells. Once taken up by APCs, VLPs are processed and presented to T cells, which can trigger the activation of B cells to produce antibodies against the displayed antigen. Because VLPs resemble the structure and composition of native viruses, they are highly effective at inducing both humoral and cellular immune responses. Generally, VLPs range in size from approximately 20 to 200 nanometers (nm). Compared to a

Application Details

	cell-based immunization approach, their smaller size can optimize the immune response to target the specific antigen displayed on the surface of the engineered VLPs.
Restrictions:	For Research Use only

Handling

Format:	Liquid
Buffer:	Supplied as 0.22μm filtered solution in PBS (pH 7.4). Notice: If you need it for immunization, Do Not use any adjuvant.
Storage:	-80 °C
Storage Comment:	Valid for 12 months from date of receipt when stored at -80°C.,Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.
Expiry Date:	12 months

Images



Size-exclusion chromatography-High Pressure Liquid Chromatography

Image 1. The purity of Cynomolgus GPRC5D VLP is greater than 95 % as determined by SEC-HPLC.



ELISA

Image 2. Immobilized Cynomolgus GPRC5D VLP (100 µL/well) at 5 µg/mL (100 µL/Well) on the plate. Dose response curve for Anti-GPRC5D Antibody, hFc Tag with the EC50 of 3.8 µg/mL determined by ELISA.